SIGN GUIdeline: diagnosis and management of delirium Ailsa Stein, Programme Manager, SIGN

Scottish Intercollegiate Guidelines Network Public funding but professional ownership evidence-based clinical guidelines produced using transparent methodology internationally validated methodology .

SIGN Delirium guideline development group Consultant Physicians A & E Consultant Consultant Psychiatrists Consultant in Geriatricians General Practitioner SIGN Nurse Practitioner Pharmacist Health economist Consultant in Critical Care and Anaesthesia Lay representatives Anaesthetist

Patient/carer issues identified previously by Healthcare Improvement Scotland in relation to delirium   Value of family members – skills and experience in detecting early warning signs Suitable approach from staff Education and training for staff – early warning signs Role of NHS 24 in getting expert knowledge from carers Opportunity to discuss dreams or nightmares Support for carers Being kept in the loop - updates for family members Staff could suggest to families keeping a diary

Key questions What assessment tool(s) should be used to detect delirium and when? What tool(s) should be used for monitoring purposes and when should they be used? What (other) investigations are useful when assessing a patient for delirium? What risk reduction strategies for patients at risk of delirium are effective? What are the most effective non-pharmacological strategies for managing patients with delirium? What are the most effective pharmacological strategies for managing patients with delirium? What follow-up care should patients receive after experiencing delirium?

Key questions Adults over 18 years at risk of, or experiencing, delirium Home, long-term care, hospital, hospice Excludes: delirium secondary to alcohol, patients with delirium tremens, paediatric delirium Comborbidities considered: dementia, depression, frailty, head injury, learning disability, Parkinson’s disease, stroke

Key questions What assessment tool(s) should be used to detect delirium and when? What tool(s) should be used for monitoring purposes and when should they be used? Tools considered: 4AT, CAM, 3D CAM, Delirium Observation Screening Scale, SQID, MDAS, RADAR, DRS-R98, ICD-SC, CAM-ICU, Modified RASS, Family CAM (FAM- CAM), Brief CAM (B-CAM), NU desk, Organic Brain Syndrome (OBS) scale Comparators: DSM 5, ICD 10, between tools Outcomes: sensitivity, specificity, evidence of adherence in clinical practical

Key questions 3. What (other) investigations are useful when assessing a patient for delirium? imaging (CT or MRI scans) lumbar puncture electroencephalogram (EEG) testing for antibodies for autoimmune encephalitis toxicology screening Comparison: usual care Outcomes: sensitivity, specificity, cost effectiveness

Key questions 4. What risk reduction strategies for patients at risk of delirium are effective? Non-pharmacological: hydration catheterization avoidance sensory impairment constipation sleep hygiene and promotion falls prevention and mobility providing means of communication impact of ward moves environmental factors proactive screening of delirium and pre-existing cognitive impairment including dementia Pharmacological: medication reconciliation pain relief antipsychotics and benzodiazepines sedation for night-time sleep

Key questions 5. What are the most effective non-pharmacological strategies for managing patients with delirium? staff behavioural adaptations (calm manner, one-to-one nursing, cognitive stimulation, reassurance, reorientation, distraction/de-escalation techniques) environmental adaptations (single room, lighting, clear signage for orientation, familiar objects, family input, minimise bed moves, address sensory impairment, OT, sleep promotion, facilitating mobility) address specific causes of stress (pain, hunger, feeling hot or cold, thirsty, urinary retention, specific fears, not understanding what is happening, hallucinations, delusions, aggression, agitation, and searching)

Key questions 6. What are the most effective pharmacological strategies for managing patients with delirium? antipsychotics benzodiazepines acetylcholinesterase inhibitors melatonin antidepressants dexmedetomidine clonidine propanolol withdrawal of culprit drugs

Key questions 7. What follow-up care should patients receive after experiencing delirium? Screening for: dementia functional psychiatry disorders – PTSD, depression

Evidence review

Forming recommendations Help clinicians with decision-making Systematically summarise the evidence base Consider the quality of the evidence base Balance the benefits and harms Consider the realities of healthcare delivery Create evidence-based, implementable recommendations

Forming recommendations Quality of evidence Applicability quantity of evidence consistency of results relevance to the target population any publication bias benefits harms impact on patients (patient preferences) feasibility (eg cost, service provision)

Drafting the guideline Evidence statement Evidence level A Cochrane Review found ibuprofen to be superior to placebo in all doses between 200 mg to 600 mg for pain free at two hours and sustained pain relief at 24 hours for patients with acute migraine with moderate to severe baseline pain. For two hour pain free the NNT was 9.7 for 200 mg and 7.2 for 400 mg.23 1++ R Ibuprofen 400 mg is recommended as first line treatment for patients with acute migraine. Recommendation

Additional content Recommendations for further research Provision of information for patients and carers Audit points Cost impact analysis (if needed)

Consultation www.sign.ac.uk open consultation peer review early 2018

Publication and implementation August 2018 www.sign.ac.uk

www.sign.ac.uk ailsa.stein@nhs.net